Co-pay accumulator adjustment programs are meant to ensure that individuals are responsible for the full amount of their insurance deductible, which should help promote healthcare consumerism, according to Bruce Sherman, MD, chief medical officer of the National Alliance of Healthcare Purchaser Coalitions.
Co-pay accumulator adjustment programs are meant to ensure that individuals are responsible for the full amount of their insurance deductible, which should help promote healthcare consumerism, according to Bruce Sherman, MD, chief medical officer of the National Alliance of Healthcare Purchaser Coalitions.
Transcript
What are co-pay accumulator programs and what purpose are they supposed to serve?
The intent of co-pay accumulator programs is to ensure that individuals who elect to enroll in a high-deductible or consumer-directed health plan fulfill the obligation of their enrollment in that plan to pay for the deductible in its full amount before the health plan or the benefit plan kicks in to support their healthcare needs.
The co-pay accumulator adjustment programs serve to prevent individuals from having any funds credited toward their deductible that come from an outside entity, such as a pharmaceutical manufacturer, that prior to about 2017 were being counted toward the patient contribution. Now with the implementation of co-pay accumulator adjustment programs, the [pharmacy benefit managers] are able to identify the source of funds, whether they are coming from the patients, whether they’re coming from a third-party source, and attribute those to the deductible or not based on the particular plan design.
So the accumulator program specifically is intended to prevent any contribution from outside of the patient from being credited toward the individual’s deductible, and that, at least theoretically, should help promote healthcare consumerism by ensuring that patients are responsible for that full amount of the deductible as the plan depicts.
Redefining Long COVID Care With Personalized Treatment
March 20th 2025To mark the 5-year anniversary of the COVID pandemic, The American Journal of Managed Care® spoke with Noah Greenspan, DPT, PT, CCS, EMT-B, cardiopulmonary physical therapist and director of the Pulmonary Wellness and Rehabilitation Center in New York City.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
How Mirdametinib Improves QOL for People With NF1-Associated Plexiform Neurofibromas
March 18th 2025Christopher L. Moertel, MD, University of Minnesota, discusses the trial data that helped get mirdametinib approved and what providers can do to keep measuring quality of life (QOL) improvements.
Read More
Advances in Gene Therapy, Neuroregeneration at the Forefront of MDA 2025
March 13th 2025Look ahead to this year's Muscular Dystrophy Association (MDA) meeting, which will feature discussions on the latest gene therapies, clinical trial data, policy considerations, and more in the realm of neuromuscular disease.
Read More